scFurosemide Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure: The FreEDom-HF Study

• Published in: Journal of cardiac failure 2018-08, Vol.24 (8), p.S58-S58
• Main Authors: Bensimhon, Daniel R., Peacock, W. Frank, Weintraub, William S., Myers, Rene, Carter, John A., Deering, Katie, Medicis, Joseph J., Mohr, John
• Format: Article
• Language: English
• ISSN: 1071-9164; 1532-8414
• DOI: 10.1016/j.cardfail.2018.07.261

Heart failure (HF) affects 6 5 million adults in the United States, a figure that is expected to grow to 8 million by 2030 In the United States, HF is implicated as the cause of at least 1-2 million hospitalizations and 700,000 emergency department visits annually Approximately 90% of patients presenting to the emergency department (ED) with worsening HF are admitted to the hospital; however, it has been reported that up to 50% of ED patients with HF could be safely discharged after a brief period of observation. The FreEDom-HF study aims to evaluate the safe admission avoidance, costs and 30-day outcomes of patients treated with subcutaneous furosemide outside the hospital versus patients receiving intravenous furosemide in the hospital This adaptive clinical trial will include a prospective treatment arm of patients presenting to the ED with worsening HF who would be expected to require intravenous furosemide for up to 3 days but will instead receive subcutaneous furosemide outside the hospital HF-related medical resource utilization and associated direct medical costs incurred over 30-days will be collected and compared to a propensity-matched historical control arm obtained from an administrative claims database The control arm will be populated with HF patients who presented to the ED and were admitted to the hospital for fewer than 72 hours and received intravenous diuretics Diagnostic codes and resource utilization during the hospital stay will be utilized and ratios of 1:1 to 4:1 will be explored to optimize matching precision Health-related quality of life and patient satisfaction will be assessed in prospective subcutaneous furosemide cohort The FREEDOM-HF study began enrollment in June 2018 The FREEDOM- HF study will determine the real-world evidence that subcutaneous furosemide will have on decreasing admissions, costs, and improving quality of life in HF patients presenting to the ED with worsening HF